LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prothrombin Time Derived from POC Test Compared to Laboratory Test

By LabMedica International staff writers
Posted on 17 Feb 2015
Print article
Roche\'s CoaguChek XS system for Prothrombin time/international normalized ratio
The CoaguChek XS system for Prothrombin time/international normalized ratio (Photo courtesy of ROCHE DIAGNOSTICS CORP)
Prothrombin time/international normalized ratio (PT/INR) is used for dosing and monitoring oral anticoagulant therapy (OAT) based on warfarin, as the therapeutic range of warfarin is narrow and there is a considerable variation in inter- and intra-individual pharmacologic response.

One of the most widely used point-of-care (POC) devices to evaluate prothrombin time for monitoring oral anticoagulant therapy is unlike other laboratory methods, as it detects electrical signals produced by thrombin activity to derive the international normalized ratio (INR).

Scientists at Yonsei University College of Medicine (Seoul, Korea) collected 91 venous blood samples submitted for fibrinogen testing to the clinical laboratory. Platelet-poor plasma was obtained by centrifugation. The fibrinogen level was measured using Fibrinogen-C XL reagent (Instrumentation Laboratory; Milan, Italy) via Clauss method using ACL TOP (Beckman Coulter; Fullerton, CA, USA). Samples were selected after fibrinogen testing according to the fibrinogen level. PT INR was measured by both the laboratory method and CoaguChek XS (Roche Diagnostics; Mannheim, Germany).

The samples were stratified into low, mid, and high fibrinogen groups by fibrinogen levels of <130 mg/dL, 130–450 mg/dL, and >450 mg/dL, respectively. The mean INR difference of the low fibrinogen group was significantly different from that of the mid or high fibrinogen group. In the low fibrinogen group, CoaguChek XS INR showed a negative bias compared with the laboratory INR, while the mid and high fibrinogen groups had positive bias.

The authors concluded that that patient selection according to fibrinogen status should precede the implementation of POC testing using CoaguChek XS. Also, periodic comparisons between CoaguChek XS and laboratory INR results should be continued during the use of CoaguChek XS. The study was published on January 31, 2015, in the Journal of Clinical Laboratory Analysis.

Related Links:

Yonsei University College of Medicine
Instrumentation Laboratory
Roche Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more